- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00724126
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Anniston, Alabama, Forente stater, 36207
-
Birmingham, Alabama, Forente stater, 35205
-
Huntsville, Alabama, Forente stater, 35801
-
-
Arizona
-
Tempe, Arizona, Forente stater, 85282
-
-
California
-
Anaheim, California, Forente stater, 92801
-
Carmichael, California, Forente stater, 95608
-
Chula Vista, California, Forente stater, 91910
-
Concord, California, Forente stater, 94520
-
Garden Grove, California, Forente stater, 92840
-
Laguna Hills, California, Forente stater, 92653
-
Lakewood, California, Forente stater, 90712
-
Los Angeles, California, Forente stater, 90048
-
Monterey, California, Forente stater, 93940
-
Orange, California, Forente stater, 92868
-
Roseville, California, Forente stater, 95661
-
San Carlos, California, Forente stater, 94070
-
San Francisco, California, Forente stater, 94117
-
-
Connecticut
-
Bristol, Connecticut, Forente stater, 06010
-
Hamden, Connecticut, Forente stater, 06518
-
-
Delaware
-
Newark, Delaware, Forente stater, 19713
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33486
-
Hollywood, Florida, Forente stater, 33021
-
Largo, Florida, Forente stater, 33777
-
New Port Richey, Florida, Forente stater, 34655
-
New Smyrna Beach, Florida, Forente stater, 32168
-
Port Orange, Florida, Forente stater, 32127
-
Saint Petersburg, Florida, Forente stater, 33709
-
Tampa, Florida, Forente stater, 33607
-
Zephyrhills, Florida, Forente stater, 33542
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
-
Macon, Georgia, Forente stater, 31201
-
-
Indiana
-
Elkhart, Indiana, Forente stater, 46514
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
-
Topeka, Kansas, Forente stater, 66606
-
-
Kentucky
-
Bowling Green, Kentucky, Forente stater, 42104
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
-
Monroe, Louisiana, Forente stater, 71201
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21229
-
Elkridge, Maryland, Forente stater, 21075
-
-
Massachusetts
-
Wellesley, Massachusetts, Forente stater, 02481
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
-
Troy, Michigan, Forente stater, 48098
-
Wyoming, Michigan, Forente stater, 49519
-
-
Missouri
-
Mexico, Missouri, Forente stater, 65265
-
-
New Jersey
-
Sicklerville, New Jersey, Forente stater, 08081
-
Voorhees, New Jersey, Forente stater, 08043
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87102
-
-
New York
-
Great Neck, New York, Forente stater, 11021
-
Mineola, New York, Forente stater, 11501
-
New York, New York, Forente stater, 10016
-
North Massapequa, New York, Forente stater, 11758
-
Pomona, New York, Forente stater, 10970
-
Stony Brook, New York, Forente stater, 11790
-
-
North Carolina
-
Boone, North Carolina, Forente stater, 28607
-
Chapel Hill, North Carolina, Forente stater, 27514
-
Charlotte, North Carolina, Forente stater, 28209
-
Greensboro, North Carolina, Forente stater, 27408
-
Greensboro, North Carolina, Forente stater, 27403
-
New Bern, North Carolina, Forente stater, 28562
-
Wilmington, North Carolina, Forente stater, 28401
-
Winston-Salem, North Carolina, Forente stater, 27103
-
-
Ohio
-
Canton, Ohio, Forente stater, 44718
-
Cincinnati, Ohio, Forente stater, 45242
-
Dayton, Ohio, Forente stater, 45415
-
-
Pennsylvania
-
Downingtown, Pennsylvania, Forente stater, 19335
-
Newtown, Pennsylvania, Forente stater, 18940
-
Pittsburgh, Pennsylvania, Forente stater, 15206
-
Sayre, Pennsylvania, Forente stater, 18840
-
-
South Carolina
-
Anderson, South Carolina, Forente stater, 29621
-
Columbia, South Carolina, Forente stater, 29203
-
-
Tennessee
-
Bristol, Tennessee, Forente stater, 37620
-
Chattanooga, Tennessee, Forente stater, 37421
-
Franklin, Tennessee, Forente stater, 37067
-
Germantown, Tennessee, Forente stater, 38138
-
Jackson, Tennessee, Forente stater, 38301
-
Kingsport, Tennessee, Forente stater, 37660
-
-
Texas
-
El Paso, Texas, Forente stater, 79902
-
Houston, Texas, Forente stater, 77024
-
Lewisville, Texas, Forente stater, 75057
-
Plano, Texas, Forente stater, 75075
-
San Antonio, Texas, Forente stater, 78229
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84107
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05401
-
-
Virginia
-
Chesapeake, Virginia, Forente stater, 23320
-
Fairfax, Virginia, Forente stater, 22031
-
-
Washington
-
Spokane, Washington, Forente stater, 99208
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
-
Milwaukee, Wisconsin, Forente stater, 53215
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.
- Colonoscopy within 2 years as part of IBS diagnostic evaluation.
- Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.
Exclusion Criteria:
- Symptoms of constipation.
- History of other gastrointestinal diseases.
- Type 1 or 2 diabetes.
- Lactose intolerance not controlled by lactose-free diet.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Placebo
Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
|
|
Eksperimentell: Rifaximin
Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
Tidsramme: 4 weeks
|
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? [Yes/No]" |
4 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)
Tidsramme: 4 weeks
|
The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? [Yes/No]." |
4 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Enoch Bortey, Bausch Health Americas, Inc.
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
- Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RFIB3008
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Non-Constipation Irritable Bowel Syndrome
-
Seoul National University HospitalUkjentSunn | Kronisk forstoppelse | Constipated Irritable Bowel Syndrome
-
National Cancer Institute (NCI)AvsluttetTilbakevendende kutant T-celle non-Hodgkin lymfom | Tilbakevendende Mycosis Fungoides/Sezary Syndrome | Trinn III kutant T-celle non-Hodgkin lymfom | Stage III Mycosis Fungoides/Sezary syndrom | Stadium IV Kutant T-celle non-Hodgkin lymfom | Stage IV Mycosis Fungoides/Sezary syndrom | Fase I Kutant... og andre forholdForente stater
-
Northwestern UniversityAmgenAvsluttetTilbakevendende kutant T-celle non-Hodgkin lymfom | Tilbakevendende Mycosis Fungoides/Sezary Syndrome | Trinn III kutant T-celle non-Hodgkin lymfom | Stadium IV Kutant T-celle non-Hodgkin lymfom | Fase I Kutant T-celle non-Hodgkin lymfom | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage IB Mycosis... og andre forholdForente stater
-
Kevin Cooper MDNational Cancer Institute (NCI)FullførtTilbakevendende kutant T-celle non-Hodgkin lymfom | Tilbakevendende Mycosis Fungoides/Sezary Syndrome | Fase I Kutant T-celle non-Hodgkin lymfom | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage IB Mycosis Fungoides/Sezary Syndrome | Trinn II kutant T-celle non-Hodgkin lymfom | Stage IIA Mycosis...Forente stater
-
National Cancer Institute (NCI)FullførtAnaplastisk storcellet lymfom | Angioimmunoblastisk T-celle lymfom | Tilbakevendende voksen T-celle leukemi/lymfom | Tilbakevendende kutant T-celle non-Hodgkin lymfom | Tilbakevendende Mycosis Fungoides/Sezary Syndrome | Tynntarms lymfom | Trinn III kutant T-celle non-Hodgkin lymfom | Stage III Mycosis... og andre forholdForente stater
-
Marcela V. Maus, M.D.,Ph.D.Kite, A Gilead CompanyAktiv, ikke rekrutterendeNon Hodgkin lymfom | Nevrotoksisitet | Nevrotoksisitetssyndromer | Cytokinfrigjøringssyndrom | Refraktært non-Hodgkin lymfom | Residiverende non-hodgkin lymfomForente stater
-
Emory UniversityNational Cancer Institute (NCI)RekrutteringMogamulizumab og ekstrakorporeal fotoferese for behandling av sezary syndrom eller mycosis fungoidesMycosis Fungoides | Sezary syndrom | Primært kutant T-celle non-Hodgkin lymfomForente stater
-
Maastricht UniversityHar ikke rekruttert ennåIrritabel tarm-syndrom | Non-coeliac Wheat Sensitivity (NCWS)
-
Targazyme, Inc.UkjentLymfom | Leukemi | Hodgkins lymfom | Transplantasjonsinfeksjon | Myelodysplastisk syndrom (MDS) | Non-Hodgkins lymfom (NHL) | Blod- og margtransplantasjonForente stater
-
Northwestern UniversityNational Cancer Institute (NCI); CelgeneAktiv, ikke rekrutterendePerifert T-celle lymfom | Anaplastisk storcellet lymfom | Angioimmunoblastisk T-celle lymfom | Voksen nesetype Ekstranodal NK/T-celle lymfom | Hepatosplenisk T-celle lymfom | Trinn III kutant T-celle non-Hodgkin lymfom | Stadium IV Kutant T-celle non-Hodgkin lymfom | Fase I Kutant T-celle non-Hodgkin... og andre forholdForente stater
Kliniske studier på Placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Fullført